Inventor · disambiguated record
Rok Grahek
Also filed as: GRAHEK ROK
10 granted patents·16 pending applications·30 citations·filing 1996–2020
84Inventor score
Top patents by PatentIndex Score
26 records- 0172US9149460B2Coated particles and pharmaceutical dosage formsHUMAR VLASTA·Filed 2007·Granted Oct 6, 2015·2 cites·20 claims
- 0265US7141602B2Process for obtaining HMG-CoA reductase inhibitors of high purityLEK PHARMACEUTICALS·Filed 2003·Granted Nov 28, 2006·1 cites·5 claims
- 0363US2010056605A1Oxidative degradation products of atorvastatin calciumLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 0462US9453030B2Oxidative degradation products of atrovastatin calciumLEK PHARMACEUTICALS·Filed 2014·Granted Sep 27, 2016·0 cites·9 claims
- 0562US8435938B2Pure vancomycin hydrochlorideGRAHEK ROK·Filed 2005·Granted May 7, 2013·1 cites·9 claims
- 0661US8309719B2Process for the preparation of methyl ester of rosuvastatinBASTARDA ANDREJ·Filed 2008·Granted Nov 13, 2012·1 cites·5 claims
- 0759US6695969B1Process for obtaining HMG-CoA reductase inhibitors of high purityLEK PHARMACEUTICALS·Filed 1999·Granted Feb 24, 2004·18 cites·26 claims
- 0855US9907757B2Coated particles and pharmaceutical dosage formsLEK PHARMACEUTICALS·Filed 2015·Granted Mar 6, 2018·0 cites·8 claims
- 0954US8044086B2Oxidative degradation products of atorvastatin calciumLEK PHARMACEUTICALS·Filed 2005·Granted Oct 25, 2011·0 cites·3 claims
- 1054US2010305087A1Active pharmaceutical ingredient on a solid support, amorphous and with an improved solubilityLEK PHARMACEUTICALS·Filed 2008·Application pending·0 cites
- 1151US2006093680A1Coated particles and pharmaceutical dosage formsHUMAR VLASTA·Filed 2004·Application pending·0 cites
- 1246US2009012150A1Stablized Pharmaceutical Composition Comprising an Amorphous Active SubstanceGRAHEK ROK·Filed 2007·Application pending·0 cites
- 1346US2020163882A1Solid Pharmaceutical Compositions Of Androgen Receptor AntagonistsLEK PHARMACEUTICALS·Filed 2020·Application pending·0 cites
- 1446US2004077708A1Stablized pharmaceutical composition comprising an amorphous active substanceFiled 2003·Application pending·0 cites
- 1545US2010219063A1Oxidative degeneration products of atorvastatin calciumLEK PHARMACEUTICALS·Filed 2010·Application pending·0 cites
- 1643US2008242725A1Pharmaceutical CompositionKERC JANEZ·Filed 2005·Application pending·0 cites
- 1742US2007032549A1Process for obtaining HMG-CoA reductase inhibitors of high purityGRAHEK ROK·Filed 2006·Application pending·0 cites
- 1842US2016256433A1Formulations Containing Amorphous DapagliflozinSANDOZ AG·Filed 2014·Application pending·0 cites
- 1941US2011112165A1Atorvastatin-aliskirenKOCIJAN ANDREJ·Filed 2009·Application pending·0 cites
- 2041US2019175543A1Formulations Containing Amorphous DapagliflozinSANDOZ AG·Filed 2019·Application pending·0 cites
- 2140US5854390AChromatographic purification of vancomycin hydrochloride by use of preparative HPLCLEK TOVARNA FARMACEVTSKIH·Filed 1996·Granted Dec 29, 1998·7 cites·34 claims
- 2233US10702477B2Afatinib-containing formulationSANDOZ AG·Filed 2016·Granted Jul 7, 2020·0 cites·16 claims
- 2333US2017258761A1Pharmaceutical Compositions Comprising CanagliflozinSANDOZ AG·Filed 2015·Application pending·0 cites
- 2432US2007298108A1Pharmaceutical FormulationSVETE PETER·Filed 2005·Application pending·0 cites
- 2528US2016346207A1Solid Pharmaceutical Compositions Of Androgen Receptor AntagonistsLEK PHARMACEUTICALS·Filed 2015·Application pending·0 cites
- 2621US2012088774A1Active pharmaceutical ingredient adsorbed on solid supportGRAHEK ROK·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →